Presentations at the upcoming Alzheimer’s Association International Conference include data comparing P-tau217 blood biomarker tests with amyloid PET, along with new long-term safety findings for donanemab.
Eli Lilly and Company announced it will present 16 abstracts at the 2026 Alzheimer’s Association International Conference in London from July 12 to 15. The scientific program includes new data comparing the diagnostic performance of P-tau217 blood biomarker tests with amyloid positron emission tomography (PET) in cognitively unimpaired individuals.
The presentations span imaging science, health economics, real-world prescribing evidence, and patient-centered outcomes, according to the company.
Advancing Blood-Based Diagnostics
Samantha Burnham, PhD, senior research scientist at Eli Lilly and Company, is scheduled to present data on July 15 showing that P-tau217 blood biomarker assays demonstrated strong rule-in performance for identifying Alzheimer’s disease pathology. The results indicate that the assays performed comparably to amyloid PET for identifying pathology in cognitively unimpaired individuals.
While blood biomarker tests and amyloid PET agents are not currently indicated for use in cognitively unimpaired individuals, the results “generate support for a potentially scalable, accessible alternative to specialized imaging in the future,” according to a company release.
Evidence for Amyloid-Targeting Treatment
The conference program also features new clinical evidence for Kisunla (donanemab-azbt), an amyloid-targeting treatment for adults with early symptomatic Alzheimer’s disease. Findings from the TRAILBLAZER-ALZ 6 and TRAILBLAZER-ALZ 2 long-term extension trials will be presented to address clinical questions regarding safety and biomarker durability.
The research provides insights into safety through modified titration and corticosteroid pretreatment. Additionally, the company will present evidence on the potential durability of clinical benefit from the long-term extension studies, according to the release.
Methodology and Data Analysis
Lars Raket, PhD, will discuss the use of external controls versus internal extrapolation in the TRAILBLAZER-ALZ 2 long-term extension. The analysis addresses how long-term outcomes are measured and interpreted in clinical trials, reflecting a “commitment to the scientific rigor that underpins credible long-term evidence generation,” says Lars Raket, PhD, Eli Lilly and Company, in a release.
Other research to be presented includes the application of Natural Language Processing algorithms to identify intracerebral hemorrhage and amyloid-related imaging abnormalities in US electronic medical records. The company will also present risk algorithms designed to predict elevated plasma P-tau217 status and healthcare utilization drivers during preclinical disease progression.
ID 59941415 © Csaba Deli | Dreamstime.com
